SEDLÁKOVÁ, Veronika, M. AHUMADA, E. J. SUURONEN a E. I. ALARCON. Building new cardiac vasculature and myocardium: where are we at? Current opinion in cardiology. Philadelpha, PA: Rapid Science Publishers, 2021, roč. 36, č. 6, s. 728-734. ISSN 0268-4705. Dostupné z: https://dx.doi.org/10.1097/HCO.0000000000000905.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Building new cardiac vasculature and myocardium: where are we at?
Autoři SEDLÁKOVÁ, Veronika (203 Česká republika, domácí), M. AHUMADA, E. J. SUURONEN a E. I. ALARCON (garant).
Vydání Current opinion in cardiology, Philadelpha, PA, Rapid Science Publishers, 2021, 0268-4705.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.108
Kód RIV RIV/00216224:14110/21:00123962
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1097/HCO.0000000000000905
UT WoS 000703608800009
Klíčová slova anglicky 3D bioprinting; biomaterials; cardiac tissue; cell therapy; tissue engineering
Štítky 14110517, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 1. 2. 2022 10:35.
Anotace
Purpose of review This review describes the latest advances in cell therapy, biomaterials and 3D bioprinting for the treatment of cardiovascular disease. Recent findings Cell therapies offer the greatest benefit for patients suffering from chronic ischemic and nonischemic cardiomyopathy. Rather than replacing lost cardiomyocytes, the effects of most cell therapies are mediated by paracrine signalling, mainly through the induction of angiogenesis and immunomodulation. Cell preconditioning, or genetic modifications are being studied to improve the outcomes. Biomaterials offer stand-alone benefits such as bioactive cues for cell survival, proliferation and differentiation, induction of vascularization or prevention of further cardiomyocyte death. They also provide mechanical support or electroconductivity, and can be used to deliver cells, growth factors or drugs to the injured site. Apart from classical biomaterial manufacturing techniques, 3D bioprinting offers greater spatial control over biomaterial deposition and higher resolution of the details, including hollow vessel-like structures. Cell therapy induces mainly angiogenesis and immunomodulation. The ability to induce direct cardiomyocyte regeneration to replace the lost cardiomyocytes is, however, still missing until embryonic or induced pluripotent stem cell use becomes available. Cell therapy would benefit from combinatorial use with biomaterials, as these can prolong cell retention and survival, offer additional mechanical support and provide inherent bioactive cues. Biomaterials can also be used to deliver growth factors, drugs, and other molecules. 3D bioprinting is a high-resolution technique that has great potential in cardiac therapy.
VytisknoutZobrazeno: 28. 7. 2024 15:13